Gastroenterology Research and Practice / 2017 / Article / Tab 1

Research Article

Factors Related to Significant Improvement of Estimated Glomerular Filtration Rates in Chronic Hepatitis B Patients Receiving Telbivudine Therapy

Table 1

Baseline characteristics of the chronic hepatitis B patients () treated with telbivudine therapy.

n (%)

Age, years (mean ± SD)48 ± 13
Gender, male99 (77)
HBeAg status, positive46 (36)
Genotype, B/C/unknown73/23/33
Treatment-naïve112 (87)
Liver cirrhosis31 (24)
Hepatic decompensation20 (16)
Hepatocellular carcinoma13 (10)
Diabetes mellitus15 (12)
Hypertension13 (10)
Contrast-medium exposure13 (10)
Albumin, g/dL (IQR)4.3 (4.0–4.5)
Bilirubin, mg/dL (IQR)0.9 (0.7–1.3)
AST, U/L (IQR)80 (51–162)
ALT, U/L (IQR)158 (85–337)
Creatinine (mg/dL) (mean ± SD)1.06 ± 0.59
CKD-EPI (mL/min/1.73 m2) (mean ± SD)85.04 ± 18.27
Baseline HBV DNA, log IU/mL (IQR)5.9 (4.8–7.5)
Baseline HBV DNA > 7 log IU/mL42 (33)

ALT: alanine transaminase; AST: aspartate transaminase; CKD-EPI: the formula of Chronic Kidney Disease Epidemiology Collaboration; HBeAg: hepatitis B e-antigen; IQR: interquartile range; SD: standard deviation.

We are committed to sharing findings related to COVID-19 as quickly as possible. We will be providing unlimited waivers of publication charges for accepted research articles as well as case reports and case series related to COVID-19. Review articles are excluded from this waiver policy. Sign up here as a reviewer to help fast-track new submissions.